[go: up one dir, main page]

SG10201912984WA - Antibodies and methods of use thereof - Google Patents

Antibodies and methods of use thereof

Info

Publication number
SG10201912984WA
SG10201912984WA SG10201912984WA SG10201912984WA SG10201912984WA SG 10201912984W A SG10201912984W A SG 10201912984WA SG 10201912984W A SG10201912984W A SG 10201912984WA SG 10201912984W A SG10201912984W A SG 10201912984WA SG 10201912984W A SG10201912984W A SG 10201912984WA
Authority
SG
Singapore
Prior art keywords
antibodies
methods
Prior art date
Application number
SG10201912984WA
Inventor
Nicholas S Wilson
Jeremy D Waight
Gerd Ritter
David Schaer
Daniel Hirschhorn-Cymerman
Taha Merghoub
Ekaterina V Breous-Nystrom
Volker Seibert
Takemasa Tsuji
Olivier Leger
Dennis J Underwood
Dijk Marc Van
Original Assignee
Agenus Inc
Memorial Sloan Kettering Cancer Center
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc, Memorial Sloan Kettering Cancer Center, Ludwig Inst For Cancer Res Ltd filed Critical Agenus Inc
Publication of SG10201912984WA publication Critical patent/SG10201912984WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG10201912984WA 2015-12-02 2016-12-02 Antibodies and methods of use thereof SG10201912984WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262369P 2015-12-02 2015-12-02
US201662419911P 2016-11-09 2016-11-09

Publications (1)

Publication Number Publication Date
SG10201912984WA true SG10201912984WA (en) 2020-03-30

Family

ID=58797808

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804265XA SG11201804265XA (en) 2015-12-02 2016-12-02 Antibodies and methods of use thereof
SG10201912984WA SG10201912984WA (en) 2015-12-02 2016-12-02 Antibodies and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201804265XA SG11201804265XA (en) 2015-12-02 2016-12-02 Antibodies and methods of use thereof

Country Status (13)

Country Link
US (5) US11447557B2 (en)
EP (1) EP3383430A4 (en)
JP (3) JP7089470B2 (en)
KR (1) KR20180083944A (en)
CN (2) CN116063542A (en)
AU (1) AU2016364889B2 (en)
CA (1) CA3007233A1 (en)
IL (2) IL299072A (en)
MA (1) MA44312A (en)
MX (1) MX2018006477A (en)
SG (2) SG11201804265XA (en)
TW (2) TWI717432B (en)
WO (1) WO2017096179A1 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692458A1 (en) 2014-05-28 2017-06-30 Агенус Инк. ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2017014188A (en) 2015-05-07 2018-04-10 Agenus Inc Anti-ox40 antibodies and methods of use thereof.
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
US20200079862A1 (en) * 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
JP7058219B2 (en) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Heterodimer antibody that binds to CD3 and PSMA
MX2018015592A (en) 2016-06-14 2019-04-24 Xencor Inc INHIBITING ANTIBODIES OF BISPECIFIC CONTROL POINTS.
UA127449C2 (en) * 2016-09-23 2023-08-30 Мерус Н.В. A BINDING MOLECULE THAT MODULATES CELL-EXPRESSED BIOLOGICAL ACTIVITY
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
JOP20190100A1 (en) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
CN108218990B (en) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 Isolated antibodies or antigen binding fragments thereof and their use in tumor therapy
CN111886256B (en) 2018-03-23 2025-01-10 百时美施贵宝公司 Anti-MICA and/or MICB antibodies and uses thereof
CN118063599A (en) 2018-07-03 2024-05-24 吉利德科学公司 Antibodies targeting HIV GP120 and methods of use
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
CN110872349A (en) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 Antibodies that bind human IL-4R, methods of making, and uses thereof
WO2020102647A1 (en) * 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
CN111375059B (en) * 2018-12-29 2024-04-16 江苏恒瑞医药股份有限公司 anti-GITR antibody pharmaceutical composition and application thereof
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
US11084832B2 (en) 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN111109198B (en) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 Method for constructing uveitis animal model
TWI762925B (en) 2019-05-21 2022-05-01 美商基利科學股份有限公司 Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
KR20220047277A (en) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 HIV Vaccines, and Methods of Making and Using the Same
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CR20220129A (en) 2019-09-30 2022-05-06 Gilead Sciences Inc HBV VACCINES AND HBV TREATMENT METHODS
CN118178645A (en) 2019-10-18 2024-06-14 四十七公司 Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (en) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1 inhibitors
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
SI4081305T1 (en) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CA3169451A1 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
TW202421168A (en) 2020-03-20 2024-06-01 美商基利科學股份有限公司 Prodrugs of 4’-c-substituted-2-halo-2’-deoxyadenosine nucleosides and methods of making and using the same
WO2021195472A1 (en) * 2020-03-26 2021-09-30 Aetio Biotherapy, Inc. Bi-specific fusion proteins for depletion of regulatory t cells
AU2021264550A1 (en) 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
EP4192474A1 (en) 2020-08-07 2023-06-14 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
CN116234909A (en) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 CD40 agonist antibodies and methods of use
CN112043696B (en) * 2020-08-26 2023-02-24 深圳市第二人民医院(深圳市转化医学研究院) Application of IDO-1 inhibitor in preparation of medicine for treating osteoarthritis
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
DK4267105T3 (en) 2020-12-28 2025-05-19 Bristol Myers Squibb Co ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
TW202241952A (en) 2020-12-31 2022-11-01 法商英耐特醫藥公司 MULTIFUNCTIONAL NATURAL KILLER(NK) CELL ENGAGERS BINDING TO NKp46 AND CD123
TW202246334A (en) 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr antagonists and methods of using the same
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
TW202348237A (en) 2021-05-13 2023-12-16 美商基利科學股份有限公司 Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
TW202313094A (en) 2021-05-18 2023-04-01 美商基利科學股份有限公司 Methods of using flt3l-fc fusion proteins
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
MX2023014762A (en) 2021-06-23 2024-01-15 Gilead Sciences Inc DIACYL GLYCEROL KINASE MODULATING COMPOUNDS.
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 diacylglycerol kinase modulating compounds
CN118139858A (en) 2021-10-28 2024-06-04 吉利德科学公司 Pyridazin-3(2H)-one derivatives
MX2024005066A (en) 2021-10-29 2024-05-24 Gilead Sciences Inc Cd73 compounds.
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PE20241341A1 (en) 2021-12-03 2024-07-03 Gilead Sciences Inc THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION
KR20240117588A (en) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Compounds for the treatment of HIV viral infection
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
JP2024545193A (en) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
LT4245756T (en) 2022-03-17 2024-11-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
KR20240165995A (en) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Combination therapy for the treatment of TROP-2 expressing cancers
TWI876305B (en) 2022-04-05 2025-03-11 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
TW202446773A (en) 2022-04-06 2024-12-01 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202400138A (en) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d modulating compounds
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
KR20250017240A (en) 2022-05-27 2025-02-04 사노피 Natural killer (NK) cell agonist binding to NKp46 and BCMA mutants with FC-modification
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN120225509A (en) 2022-12-22 2025-06-27 吉利德科学公司 PRMT5 inhibitors and uses thereof
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
TW202504592A (en) 2023-05-31 2025-02-01 美商基利科學股份有限公司 Solid forms
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
ES2281899T3 (en) 1994-05-06 2007-10-01 Institut Gustave Roussy SOLUBLE POLYPEPTIDIC FRACTIONS OF LAG-3 PROTEIN; PRODUCTION PROCEDURE; THERAPEUTIC COMPOSITION; ANTI-IDIOTIPO ANTIBODY.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6197524B1 (en) 1995-07-21 2001-03-06 Institute National De La Sante Et De La Recherche Medicale Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (en) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド CTLA-4 binding peptides for immunotherapy
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
JP2001520039A (en) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Human tumor necrosis factor receptor-like proteins, TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1053321A1 (en) 1998-02-09 2000-11-22 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
PT1060247E (en) 1998-02-24 2008-12-22 Sisters Of Providence In Orego Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1104306B1 (en) 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
KR100856446B1 (en) 1998-12-23 2008-09-04 화이자 인크. Human monoclonal antibodies to ctla-4
ES2694002T3 (en) 1999-01-15 2018-12-17 Genentech, Inc. Polypeptide comprising an Fc region of variant human IgG1
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2539411T3 (en) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receiver for B7-4 and its use
JP4093757B2 (en) 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド Human CTLA-4 antibody and use thereof
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
CA2423436A1 (en) 2000-10-02 2002-04-11 Anthony Montgomery Methods and compositions for modulating t cell activation and uses thereof
ATE489395T1 (en) 2000-12-12 2010-12-15 Medimmune Llc MOLECULES WITH LONGER HALF-LIFE, COMPOSITIONS AND THEIR USE
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US20040009174A1 (en) 2001-12-18 2004-01-15 Arndt Gregory Martin Method of treating asthma
JP4694128B2 (en) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド Compositions and methods related to TIM-3, Th1-specific cell surface molecules
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
EP1487477A4 (en) 2002-03-26 2006-07-19 Immunex Corp Methods of using flt3-ligand in immunization protocols
PE20040079A1 (en) 2002-04-03 2004-04-19 Novartis Ag INDOLYLMALEIMIDE DERIVATIVES
CN1652820A (en) 2002-04-12 2005-08-10 梅达雷克斯公司 Methods of treatment using CTLA-4 antibodies
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
WO2003106498A2 (en) 2002-06-13 2003-12-24 Crucell Holland, B.V. Agonistic binding molecules to the human ox40 receptor
ES2654064T3 (en) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
US20040115216A1 (en) 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2503457A1 (en) 2002-10-25 2004-05-06 University Of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
DE10261223A1 (en) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Increasing the immune response through substances that influence the function of natural killer cells
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
CA2511538C (en) 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
GB0303663D0 (en) 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP2008501621A (en) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Pharmaceutical composition comprising a bispecific anti-CD3, anti-CD19 antibody construct for treating a B cell related disease
CA2529307C (en) 2003-06-13 2013-12-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
PT1692516E (en) 2003-10-24 2011-03-07 Immunaid Pty Ltd Method of therapy
WO2005049085A1 (en) 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
US7691861B2 (en) 2004-01-19 2010-04-06 Novartis Ag Indolymaleimide derivatives
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
BRPI0509201A (en) 2004-03-23 2007-08-28 Biogen Idec Inc receptor coupling agents and therapeutic uses of these
JP2007530526A (en) 2004-03-26 2007-11-01 ファイザー・プロダクツ・インク Use of anti-CTLA-4 antibody
CA2565827A1 (en) 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
DE102004063494A1 (en) 2004-12-23 2006-07-13 Tegenero Ag antibody
DK2343320T3 (en) 2005-03-25 2018-01-29 Gitr Inc ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2006345852A (en) 2005-06-16 2006-12-28 Virxsys Corp Antibody conjugate
GB0512225D0 (en) 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
CN104072614B (en) * 2005-07-08 2017-04-26 生物基因Ma公司 Anti-alpha[v]beta[6] antibodies and uses thereof
US8652836B2 (en) 2005-07-29 2014-02-18 Providence Health System Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response
WO2007041171A2 (en) * 2005-09-29 2007-04-12 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
WO2007081878A2 (en) 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2007056539A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
JPWO2007060918A1 (en) 2005-11-24 2009-05-07 大日本住友製薬株式会社 Novel memory CTL induction enhancer
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human CD134 (OX40) human monoclonal antibody and method of making and using same
WO2007133290A2 (en) 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
US20080286286A1 (en) 2006-01-13 2008-11-20 Board Of Regents, The University Of Texas System Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
US20110212086A1 (en) * 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
EP2010207A4 (en) 2006-03-22 2009-12-02 Imp Innovations Ltd Compositions and methods relating to modulation of immune system components
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US20090317407A1 (en) 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US10106619B2 (en) 2006-10-04 2018-10-23 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with OX40 agonist compositions
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
JP2008278814A (en) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk Release of immune control by agonistic anti-human GITR antibody and its application
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2348052A3 (en) 2007-09-17 2011-10-26 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
EP2188630A4 (en) 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS ASSOCIATED WITH SYNERGIC RESPONSES TO ONCOGENIC MUTATIONS
ES2883176T3 (en) * 2007-11-08 2021-12-07 Prec Biologics Inc Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2707773C (en) 2007-12-14 2017-01-10 Pfizer Inc. Binding molecules to the human ox40 receptor
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
RS53688B9 (en) 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9301785B2 (en) 2008-10-21 2016-04-05 K2M, Inc. Spinal buttress plate
EP2351777B1 (en) * 2008-10-28 2015-10-28 Shionogi&Co., Ltd. Anti-muc1 antibody
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2010056898A2 (en) 2008-11-12 2010-05-20 University Of Maryland, Baltimore Rapid expression cloning of human monoclonal antibodies from memory b cells
RU2636023C2 (en) 2008-12-09 2017-11-17 Дженентек, Инк. Antibodies to pd-l1 and their application for t-cells function strengthening
LT2398498T (en) 2009-02-17 2019-01-10 Ucb Biopharma Sprl Antibody molecules having specificity for human ox40
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
KR20110124369A (en) * 2009-04-07 2011-11-16 로슈 글리카트 아게 Bispecific Antiviral Antibodies / 3 / Antiviral Antibody
US8492119B2 (en) 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
JP5808052B2 (en) 2009-05-29 2015-11-10 中外製薬株式会社 Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
BR112012004823B1 (en) 2009-09-03 2021-11-30 Merck Sharp & Dohme Corp ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, USE OF AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL COMPOSITION
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
ES2638521T5 (en) 2010-03-05 2021-03-02 Univ Johns Hopkins Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
WO2012012518A2 (en) 2010-07-20 2012-01-26 University Of Miami Inhibition of nonsense mediated decay pathways
KR101704865B1 (en) 2010-08-23 2017-02-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-ox40 antibodies and methods of using the same
WO2012064760A2 (en) 2010-11-08 2012-05-18 Biovest International, Inc. Materials and methods for directing an immune response to an epitope
CA2819829A1 (en) 2010-12-01 2012-06-07 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
KR101614997B1 (en) 2011-01-10 2016-04-22 씨티 아틀란틱 엘티디. Combination therapy including tumor associated antigen binding antibodies
KR101614195B1 (en) 2011-03-29 2016-04-20 로슈 글리카트 아게 Antibody fc variants
KR20140029446A (en) 2011-04-15 2014-03-10 컴퓨젠 엘티디. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP2014524891A (en) 2011-06-03 2014-09-25 シーティー アトランティック リミテッド MAGEA3 binding antibody
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CA3158257A1 (en) * 2011-07-11 2013-01-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
KR101685262B1 (en) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-ox40 antibodies and methods of using the same
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013049307A2 (en) 2011-09-30 2013-04-04 University Of Miami Enhanced immune memory development by aptamer targeted mtor inhibition of t cells
SI2776466T1 (en) 2011-11-11 2017-12-29 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
UA112203C2 (en) 2011-11-11 2016-08-10 Юсб Фарма С.А. Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin
PT2785683T (en) 2011-11-30 2020-04-16 Ludwig Inst For Cancer Res Ltd Inkt cell modulators and methods of using the same
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
JP6441079B2 (en) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー Bispecific antibody molecule
WO2013103800A1 (en) 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP2814844B1 (en) 2012-02-15 2017-08-02 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
CA2864688C (en) 2012-02-22 2023-09-05 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
US20150037346A1 (en) 2012-02-23 2015-02-05 Sloan-Kettering Institute For Cancer Research Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment
HK1205691A1 (en) 2012-03-02 2015-12-24 Providence Health & Services - Oregon Dual ox40 agonist/il-2 cancer therapy methods
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
KR101566538B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th17 cell and use thereof
US20140294765A1 (en) 2012-06-21 2014-10-02 Compugen Ltd. Lsr antibodies, and uses thereof for treatment of cancer
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
CA2877414A1 (en) 2012-07-30 2014-02-06 Alex Wah Hin Yeung Live and in-vivo tumor specified cancer vaccine system
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
ES2715673T3 (en) 2012-12-03 2019-06-05 Bristol Myers Squibb Co Improvement of the anti-cancer activity of immunomodulatory FC fusion proteins
HRP20210604T1 (en) * 2013-01-28 2021-05-28 Evec Inc. Humanized anti-hmgb1 antibody or antigen-binding fragment thereof
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951209A4 (en) * 2013-01-31 2016-06-22 Univ Jefferson AGONISTSFUSION PROTEIN FOR CD40-OX40 AND USES THEREOF
WO2014128245A1 (en) 2013-02-21 2014-08-28 CORAL, Sandra Dna hypomethylating agents for cancer therapy
WO2014144080A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
DK2976361T3 (en) 2013-03-18 2018-10-01 Biocerox Prod Bv HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
BR112015024553A2 (en) * 2013-04-05 2017-10-24 Genentech Inc multispecific antibody, isolated antibody, isolated nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, antibody use and method of treating individuals with disorder
TWI487995B (en) 2013-07-10 2015-06-11 Acer Inc Image capturing devices and methods
FR3008408B1 (en) 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
SG11201600293RA (en) 2013-07-15 2016-02-26 Univ Leland Stanford Junior Medical uses of cd38 agonists
KR20250007687A (en) 2013-07-16 2025-01-14 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015063339A1 (en) 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
CA2929407A1 (en) 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
BR112016013963A2 (en) 2013-12-17 2017-10-10 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
JP6590810B2 (en) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ Anti-VISTA antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
WO2015136541A2 (en) 2014-03-12 2015-09-17 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3590967A1 (en) 2014-03-24 2020-01-08 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist properties and use thereof
CA2943262A1 (en) * 2014-03-31 2015-10-08 Genentech, Inc. Anti-ox40 antibodies and methods of use
KR20160146747A (en) 2014-03-31 2016-12-21 제넨테크, 인크. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
SG10201808746QA (en) 2014-04-03 2018-11-29 Augusta University Research Institute Inc Methods for enhancing the efficacy of a tumor-directed immune response
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
EP2939690A1 (en) 2014-04-29 2015-11-04 Medizinische Hochschule Hannover Vaccine
KR20170017916A (en) * 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 T cell-redirected antigen-binding molecule for cells having immunosuppression function
EA201692458A1 (en) 2014-05-28 2017-06-30 Агенус Инк. ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
SG11201610074YA (en) * 2014-06-06 2016-12-29 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10449227B2 (en) 2014-06-27 2019-10-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
CN112546231A (en) 2014-07-09 2021-03-26 博笛生物科技有限公司 Combination therapeutic compositions and combination therapeutic methods for treating cancer
CN106794235A (en) 2014-07-18 2017-05-31 阿德瓦希斯公司 The immunogenic composition based on Listeria for causing antitumor response
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CR20170060A (en) 2014-08-19 2017-04-18 Merck Sharp & Dohme ANTI TIGIT ANTIBODIES
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
JP2017535528A (en) 2014-10-03 2017-11-30 ノバルティス アーゲー Combination therapy
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
TW201619200A (en) 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
US20160101128A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
SG10202105879XA (en) 2014-10-24 2021-07-29 Astrazeneca Ab Combination
WO2016065330A1 (en) 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
WO2016066634A2 (en) 2014-10-27 2016-05-06 Ruprecht-Karls-Universität Heidelberg Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
EP3215182B1 (en) 2014-11-05 2023-01-04 The Regents of The University of California Combination immunotherapy
BR112017008628A2 (en) 2014-11-06 2018-01-30 Genentech Inc combination therapy comprising ox40 binding agonists and tigit inhibitors
KR20170082579A (en) 2014-11-11 2017-07-14 메디뮨 리미티드 Therapeutic combinations for treating neoplasia
SMT202000579T1 (en) 2014-11-21 2020-11-10 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
KR20170090506A (en) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. Chimeric antigen receptors and methods for their use
ES2755527T3 (en) 2015-01-08 2020-04-22 BioNTech SE TNF receptor binding agonist agents
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
EP3268387A4 (en) 2015-03-11 2018-10-10 Providence Health & Services - Oregon Compositions and methods for enhancing the efficacy of cancer therapy
US11219673B2 (en) 2015-03-25 2022-01-11 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016168361A1 (en) 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
MA53243A (en) 2015-04-17 2021-06-23 Bristol Myers Squibb Co COMPOSITIONS COMPRISING A COMBINATION OF IPILIMUMAB AND NIVOLUMAB
MX2017014188A (en) 2015-05-07 2018-04-10 Agenus Inc Anti-ox40 antibodies and methods of use thereof.
ES2962885T3 (en) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Tumor necrosis factor receptor superfamily antagonist antibodies
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI732760B (en) 2015-05-29 2021-07-11 美商必治妥美雅史谷比公司 Antibodies against ox40 and uses thereof
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
SG11201804265XA (en) * 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
EP3383914A4 (en) 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHODS OF USE
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US20200079862A1 (en) 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
PT3429618T (en) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE

Also Published As

Publication number Publication date
JP2022079549A (en) 2022-05-26
CN116063542A (en) 2023-05-05
US11447557B2 (en) 2022-09-20
US20230399413A1 (en) 2023-12-14
MA44312A (en) 2018-10-10
CA3007233A1 (en) 2017-06-08
CN108883173A (en) 2018-11-23
IL299072A (en) 2023-02-01
US20200317797A1 (en) 2020-10-08
EP3383430A4 (en) 2019-12-18
KR20180083944A (en) 2018-07-23
US20200079861A1 (en) 2020-03-12
AU2016364889B2 (en) 2024-01-04
IL259495B2 (en) 2023-05-01
EP3383430A1 (en) 2018-10-10
TW202134282A (en) 2021-09-16
TW201734046A (en) 2017-10-01
SG11201804265XA (en) 2018-06-28
US20210171648A1 (en) 2021-06-10
AU2016364889A1 (en) 2018-06-07
AU2016364889A2 (en) 2018-07-19
TWI717432B (en) 2021-02-01
CN108883173B (en) 2022-09-06
JP2019501883A (en) 2019-01-24
US10836830B2 (en) 2020-11-17
JP2023105024A (en) 2023-07-28
US20230406946A1 (en) 2023-12-21
WO2017096179A1 (en) 2017-06-08
IL259495A (en) 2018-07-31
MX2018006477A (en) 2018-09-03
JP7089470B2 (en) 2022-06-22
IL259495B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL298355B2 (en) Anti-tigit antibodies and methods of use
IL259495A (en) Antibodies and methods of use thereof
IL254887A0 (en) Anti-sortilin antibodies and methods of use thereof
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
EP3310378C0 (en) Anti-cll-1 antibodies and methods of use
IL250115A0 (en) Anti-trem2 antibodies and methods of use thereof
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL259681A (en) Novel anti-claudin antibodies and methods of use